Results
Confo Therapeutics announces global licensing agreement with Lily
Confo Therapeutics, a spin-off of VUB and VIB and a leader in the discovery of medications that target G-protein coupled receptors (GPCRs), announced a worldwide licensing agreement with Eli Lilly and Company for their clinical-stage compound CFTX-1554 and related backup compounds. &nbs...
Read more
BitaGreen
Read more
Discover our new brochure: ‘A world of difference’
Want to know how the research at the five Flemish universities improves society? And what knowledge and technology transfer looks like in practice? Our new brochure introduces you in the world of research valorisation by means of 25 striking examples! Click here to see the brochure.
Read more
Hubert Rahier recycles war debris in Ukraine
Hubert Rahier, professor of physical chemistry at the VUB Materials & Chemistry research group, has been approached by the Ukrainian company Sheldor to assist in the recycling of concrete from buildings destroyed during the Russian conflict. With the support of Dutch and Belgian partn...
Read more
Building a better future, one event at a time: Konligo’s circular approach
Konligo, a VUB spin-off, is striving to become a 100% circular company.
Read more
Confo Therapeutics and Daiichi Sankyo team up to tackle CNS diseases
Confo Therapeutics, a spin-off from VUB, has teamed up with Daiichi Sankyo to discover and develop small molecule drugs targeting G-protein coupled receptors (GPCRs) associated with central nervous system (CNS) diseases, which are conditions that affect the brain and spinal cord. Confo T...
Read more
Job offer: head of VUB Foundation & Fellowship
Are you passionate about innovation and making a difference? As Head of VUB Foundation and Fellowship at TechTransfer, you'll lead a team of 4 specialists, develop policies for raising funds and manage the network of VUB Fellows.
Read more
ZEBRA ACADEMY
Read more
Presscuff
Read more